Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients

Sadeep Medhasi, Darawan Pinthong, Ekawat Pasomsut, Natchaya Vanwong, Nattawat Ngamsamut, Apichaya Puangpetch, Monpat Chamnanphon, Yaowaluck Hongkaw, Jirawat Pratoomwun, Penkhae Limsila and Chonlaphat Sukasem

1 Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand, 2 Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 3 Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center, Ramathibodi Hospital, Bangkok, Thailand, 4 Division of Virology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 5 Yuwprasat Waithayaphathum Child and Adolescent Psychiatric Hospital, Samut Prakarn, Thailand

*Correspondence: Chonlaphat Sukasem chonlaphat.suk@mahidol.ac.th

The present study sought to investigate the genetic variants in drug metabolizing enzyme and transporter (DMET) genes associated with steady-state plasma concentrations of risperidone among Thai autism spectrum disorder (ASD) patients. ASD patients taking risperidone for at least 1 month were enrolled for this pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry assay. The final analysis included 483 markers for 167 genes. Six variants, ABCB11 (c.3084A > G, c.∗420A > G, c.∗368G > A, and c.∗236G > A) and ADH7 (c.690G > A and c.−5360G > A), were found to be associated with plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety levels were associated with six gene variants, SCLO1B1 (c.−11187G > A and c.521T > C), SLCO1B3 (c.334G > T, c.699A > G, and c.1557G > A), and SLC7A5 (c.∗438C > G. Polymorphisms in UGT2B4 c.∗448A > G and CYP2D6 (c.1661G > C, c.4180G > C, and c.−2178G > A) showed considerable but not significant associations with metabolic ratio. This pharmacogenomic study identifies new genetic variants of DMET genes in monitoring risperidone therapy.

Keywords: risperidone, autism spectrum disorders, pharmacogenomics, drug metabolizing enzymes, transporters
INTRODUCTION

Autism spectrum disorder (ASD) is a neurodevelopmental disorder typically diagnosed in early childhood, and is characterized by deficits in social and linguistic communication skills, along with repetitive and stereotyped behaviors. In addition, autism patients show symptoms like irritability, aggressive attitude toward other or property, anxiety, self-injurious behavior, hyperactivity, and severe temper tantrums (Ghosh et al., 2013; Bowers et al., 2015). Risperidone, an atypical antipsychotic, is approved by the Food and Drug Administration (FDA) to treat disruptive behaviors associated with autism in children and adolescents(Cohen et al., 2013) demonstrating antagonism at dopamine D₂, serotonin 5HT₂A, and adrenergic α₂ receptors (Thyssen et al., 2010).

Plasma concentrations of risperidone and 9-hydroxy-risperidone vary among individuals, which in turn influences clinical responses and adverse-effects justifying the regular need to monitor plasma concentrations of risperidone, 9-hydroxyrisperidone, and the total active-moiety (Riedel et al., 2005; Locatelli et al., 2010). Genetic heterogeneity is commonly regarded as the main cause of this inter-individual variability. Pharmacogenomics explores the genetic causes of variability in drug responses, and aids in tailored therapy according to the individual's genetic make-up (Collins et al., 2016).

Risperidone undergoes 9-hydroxylation producing 9-hydroxyrisperidone as its active metabolite. CYP2D6 is the key enzyme for the hydroxylation of risperidone, but CYP3A4 and CYP3A5 enzymes have also been reported to play minor roles in the metabolism of risperidone (Fang et al., 1999). 9-Hydroxyrisperidone and risperidone, which have similar pharmacological activities, are collectively termed as the total active-moiety. Nevertheless, studies have shown that risperidone and 9-hydroxyrisperidone differ from each other in terms of regulation of receptor-mediated signaling pathways (Clarke et al., 2013) and 5-HT₂A/D₂ affinity ratios with differences in their therapeutic efficacies or adverse effect profiles (Koziełska et al., 2012). Risperidone and 9-hydroxyrisperidone are substrates of P-glycoprotein, an adenosine triphosphate–binding cassette (ABC) superfamily transporter, and their dispositions and absorptions might be affected by the functional status of P-glycoprotein (Nakagami et al., 2005; Corena-McLeod, 2015).

Studies have reported the inter-individual variability in pharmacokinetic and pharmacodynamics of risperidone leading to unusual exposures, an occurrence of toxic effects, and therapeutic failure. Presence of single nucleotide polymorphisms (SNPs) in the genes encoding phase I and phase II drug-metabolizing enzymes (DME) alters the activity of enzymes resulting in four possible phenotypes: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM), and ultrarapid metabolizer (UM; Zhou et al., 2009). Drug transporters are classified as influx solute carrier (SLC) family transporters and efflux ABC family transporters (Yiannakopoulou, 2013). A study analyzing the associations between drug metabolizing enzyme and transporter (DMET) polymorphisms and pharmacokinetic variability of risperidone found associations of polymorphisms in CYP2D6, TPMT, ADRB1, VKORC1, and COMT with pharmacokinetic parameters (Cabaleiro et al., 2014). ABCB1 3435C>T genotypes had significant effect on maximum concentration observed (Cₘₐₓ) of risperidone and the total active-moiety, but when ABCB1 3435C>T genotypes were combined with CYP2D6*10/*10 genotype carrying subjects, significant differences were observed in Cₘₐₓ, the area under the curve (AUC) of risperidone, and the total active-moiety as well (Yoo et al., 2011). Several polymorphisms have been studied emphasizing the influence of allelic variations among metabolic enzymes and transporters in the disposition of risperidone and its phenotypes. An association study of risperidone and 9-hydroxyrisperidone plasma levels with CYP2D6 polymorphisms in ASD patients found a significant influence of CYP2D6 variants on plasma risperidone concentrations which provides evidence of genetic variations of drug exposure and safety (Vanwong et al., 2016a). Previous studies also reported the influence of polymorphisms in DMET genes, including CYP2D6, CYP3A4, CYP3A5, ABCB1, COMT, and VKORC1 on the plasma concentrations of risperidone, 9-hydroxyrisperidone, and the total active-moiety (Jovanovic et al., 2010; Xiang et al., 2010; Suzuki et al., 2012; Cabaleiro et al., 2014). The present authors previously reported the prevalence of clinically important DMET SNPs in Thai ASD patients (Medhasi et al., 2016). The influence of CYP2D6, CYP3A5, and ABCB1 gene variants on plasma levels of risperidone, 9-hydroxyrisperidone, and the total active-moiety clearly argues for the need of pharmacogenetic testing and therapeutic drug monitoring (TDM) during risperidone therapy (Jovanovic et al., 2010). The association between genetic variants of DMET genes and steady-state plasma concentrations of risperidone, 9-hydroxyrisperidone, total active-moiety, and metabolic ratio remains unclear. The objective of the present study was to present the results of the association between genetic variants of the DMET genes and steady-state plasma concentrations of risperidone and its metabolite using the Affymetrix DMET Plus genotyping microarrays.

MATERIALS AND METHODS

Patients

Patients eligible for this study included male and female adolescents with ASD diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria and being treated with risperidone for at least 4 weeks prior to blood sample collection. Subjects enrolled were outpatients from the Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital, Samut Prakarn, Thailand for this retrospective pharmacogenomic study. Only patients having complete data on doses and duration of risperidone were recruited for this study. Dosing of the risperidone was flexible depending on response or adverse events. Risperidone dosing followed the guidelines where the starting dose of risperidone for the treatment of irritability associated with autistic disorder is 0.25 mg/day for patients weighing <20 kg and 0.5 mg/day for patients weighing ≥20 kg, with the target dose of 0.5 mg/day.
(<20 kg) and 1 mg/day (≥20 kg); effective dose range, 0.5–3 mg/day (Risperdal prescribing information, revised version 2014). Patient compliance was assessed and confirmed by the nursing staff.

Medications co-administered along with risperidone were recorded. In the case of the co-occurring attention deficit/hyperactivity disorder, stimulants were allowed to continue, provided no changes were made during the study. The exclusion criteria included patients with severe physical disabilities and currently being treated with other antipsychotics that could interfere with the pharmacokinetics of risperidone. This study was carried out in accordance with the principles of the Declaration of Helsinki, and was approved by the Ramathibodi Ethics Committee (Bangkok, Thailand). The parents of all patients included in the study received an explanation of the purpose and experimental procedures of the study. A written informed consent was obtained from the parents or guardians of the patients before the study.

**Blood Sampling and Measurements of Risperidone and 9-Hydroxyrisperidone**

Blood samples were drawn from the patients during 08:00–09:00 AM prior to the next dose of risperidone intake to determine the steady-state plasma trough concentrations (Css) of risperidone and 9-hydroxyrisperidone. Plasma samples were collected into EDTA tubes and stored at −80°C until analyzed at the laboratory for TDM in the Faculty of Medicine, Ramathibodi Hospital (Bangkok, Thailand).

The quantitative determinations ofCss of risperidone and 9-hydroxyrisperidone were performed using a modified validated liquid chromatography coupled with the tandem mass spectrometry (LC-MS/MS) method (Vanwong et al., 2016b). The instrument consisted of an Agilent 1260 HPLC system (Agilent Technologies, Santa Clara, CA, USA) coupled to an API 3200™ (SCIEX) mass spectrometer. The mass-to-charge ratio (m/z) applied for ion monitoring was 411→191 for risperidone, 428→207 for 9-hydroxyrisperidone, and 328→270 for the internal standard clozapine.

The values of intra-assay and inter-assay coefficients of variation were less than 9% for risperidone and less than 6% for 9-hydroxyrisperidone. The average accuracy was 98–110% for risperidone and 95–105% for 9-hydroxyrisperidone. The lower limit of quantifications (LLOQ) was 0.2 and 0.5 ng/ml for risperidone and 9-hydroxyrisperidone.

**DMET Plus Array and SNP Genotyping and Quality Control**

Genomic DNA was extracted from EDTA-whole blood using the MagNA Pure Compact System (Hoffman-La Roche Ltd., Basel, Switzerland). Genotyping of SNPs was performed using molecular inversion probes (MIP) technology on the Affymetrix DMET™ Plus GeneChip microarray platforms (Affymetrix Inc., Santa Clara, CA, USA). The Affymetrix DMET™ Plus microarray enables the genotyping of 1,936 genetic markers (1,931 SNPs and 5 CNVs) across 231 genes having functional significance in drug pharmacokinetics (Bonifaz-Pena et al., 2014).

The PCR product from MIP technology undergoes enzymatic fragmentation and then hybridization to the DMET microarray for SNP discrimination and genotyping (Hardenbol et al., 2003; Burmester et al., 2010). Washing and staining of DMET arrays were performed using Affymetrix fluidic stations and scanned by the Affymetrix GeneChip® Scanner 3000 (Affymetrix Inc, Santa Clara, CA, USA). The genotyping profiles of DMET SNPs were generated with Affymetrix DMET Console software (version 1.3).

Genotyping of the previously associated CYP2D6 variants, 1846G > A, rs3892097; 100C > T, rs1065852; and 2988G > A, rs28371725, with risperidone pharmacokinetics (Scordo et al., 1999; Yasui-Furukori et al., 2003; Riedel et al., 2005; Vanwong et al., 2016a) which failed the quality control (QC) in microarray analyses were identified using the PCR-based TaqMan allele discrimination method (Applied Biosystems, Carlsbad, CA, USA) for further analysis.

The QC check on the genotyping data was performed using the R package “GenABEL” and Haploview software (Barrett et al., 2005). Individuals with a <90% genotyping call rate were excluded and SNPs with more than 5% missing genotypes were excluded. Also, SNPs with minor allele frequency (MAF) < 0.05, a deviation from Hardy–Weinberg equilibrium (HWE) at P > 0.001, and variants of chromosome X were discarded from further analysis.

**Data Analyses and Statistics**

The null hypothesis for this genetic association study was that genetic variants of DMET genes are not associated with Css of risperidone and 9-hydroxyrisperidone. Results are expressed as median and the range, unless specified otherwise. The Shapiro–Wilk test was used to assess the normality of the plasma concentrations of risperidone and 9-hydroxyrisperidone. Q-Q plots, multidimensional scaling (MDS) plot, and association analysis of DMET markers with plasma concentrations of risperidone, 9-hydroxyrisperidone, the total active-moiety, and metabolic ratio were estimated using Cochran–Armitage test for trends in the GenABEL package of R version 3.1.2 (Aulchenko et al., 2007). The P-value adjusted after Bonferroni correction was set at 2.5 × 10−5. Being an exploratory study, however, genetic markers were selected as notable ones in the association analysis with a P-value less than 0.01, corrected for possible inflation due to some degree of stratification. The demographic, phenotypic measurements and linear regression analyses were calculated using the SPSS (version 17.0). P < 0.05 was considered significant in the linear regression analysis. Pairwise linkage disequilibrium analysis was performed using Haploview 4.2.

**RESULTS**

**Characteristics of the Study Cohort and Selection of DMET Markers**

After screening the 104 individuals for missing data, 103 patients passed the genotyping call rate threshold set at 90%. In addition, one patient was excluded because of being too highly identical by descent (IBS) (≥0.95). Table 1 shows the demographic
TABLE 1 | Demographic and clinical characteristics of the ASD patients.

| Characteristic                              | n  = 102 |
|---------------------------------------------|----------|
| Age, years (range)                          | 8.8 (3.4–18.6) |
| Sex                                         |          |
| Male                                        | 87 (85.3%) |
| Female                                      | 15 (14.7%) |
| Risperidone treatment                       |          |
| Risperidone dose, mg/day (range)            | 0.5 (0.2–4) |
| Risperidone duration, months (range)        | 41.62 (1.03–152.97) |
| Risperidone single medication, n (%)        | 63 (61.76) |
| Concomitant treatments, n (%)               |          |
| Methylphenidate                             | 17 (16.67) |
| Valproic acid                               | 16 (15.69) |
| Methylphenidate + valproic acid             | 5 (2.94)  |
| Methylphenidate + fluoxetine                | 1 (0.98)  |
| Pyrithioxine                                | 1 (0.98)  |
| Sertraline                                  | 1 (0.98)  |
| Median of plasma drug concentrations, ng/ml (IQR) |          |
| Risperidone                                 | 0.83 (2.22) |
| 9-hydroxyrisperidone                        | 6.75 (7.42) |
| Total active-moiety                         | 8.48 (8.54) |
| Median metabolic ratio (IQR)                | 0.08 (0.31) |

ASD, autism spectrum disorder; IQR, interquartile range.

Plasma Concentrations of Risperidone and Its Metabolite

The median (IQR) trough levels of risperidone and 9-hydroxyrisperidone measured 12 h after the last risperidone administration were 0.83 (2.22) ng/ml and 6.75 (7.42) ng/ml. The median (IQR) plasma concentration of the total active moiety was 8.48 (8.34) ng/ml as shown in Table 1. The median (IQR) metabolic ratio was 0.08 (0.31).

Association of DMET SNPs in Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone

The DMET SNPs showing significant associations with plasma concentrations of risperidone and its metabolite with a minimum P-value less than 0.01 included 22 SNPs of seven genes from the GeneChip microarray analyses; Tables 2–5. The SNPs showing a suggestive evidence of association, at P < 0.05, are shown in Supplementary Tables S1–S4.

The top significant findings of DMET SNPs associated with steady-state plasma concentrations of risperidone are shown in Table 2 and Figure 1A. Of all the DMET SNPs, six SNPs were found to be associated with plasma concentrations of risperidone (P < 0.01). Analysis showed 4 ABCB11 SNPs, including c.3084A > G (rs497692), c.*420A > G (rs496550), c.*368G > A (rs495714), and c.*236G > A (rs473351), and 2 ADH7 SNPs which included c.690G > A (rs971074) and c.–5360G > A (rs1442477) that had significant associations. The 9-hydroxyrisperidone plasma concentrations correlated significantly with the DMET genetic markers (P < 0.01) and are illustrated in Table 3 and Figure 1B. A total of six genetic variations among the SLC transporter family were associated with the plasma concentrations of 9-hydroxyrisperidone. Of the SLC1B1 polymorphisms, c.–11187G > A (rs4149015) and c.521T > C (rs4149016) had significant associations (P < 0.01). Three variants of SLC1B3, including c.334G > T (rs4149117), c.699A > G (rs7311358), and c.1557G > A (rs2053098) that had significant associations. The 9-hydroxyrisperidone plasma concentrations correlated significantly with the DMET genetic markers (P < 0.01) and are illustrated in Table 3 and Figure 1B. A total of six genetic variations among the SLC1B1 polymorphisms, c.–11187G > A (rs4149015) and c.521T > C (rs4149016) had significant associations (P < 0.01). Three variants of SLC1B3, including c.334G > T (rs4149117), c.699A > G (rs7311358), and c.1557G > A (rs2053098) that had significant associations.

Association of CYP2D6 SNPs in Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone Using TaqMan Assay

The relationships between the CYP2D6 variants (rs3892097, rs1065852, and rs28371725) and the plasma concentrations of 9-hydroxyrisperidone, the total active-moiety, and the metabolic ratio are shown in Table 6. A significant influence in the plasma concentration of risperidone (P = 0.009) was observed with CYP2D6 c.2988G > A (rs28371725), but no significance was found in the plasma concentration of 9-hydroxyrisperidone, the total active-moiety, and metabolic ratio. There was significant influence of CYP2D6 c.100C > T (rs1065852) in the metabolic ratio (P = 0.004), whereas no influence was found for plasma concentrations...
of risperidone, 9-hydroxyrisperidone, and the total active-moiety. *CYP2D6* c.1846G > A (rs3892097) did not show any associations with the plasma concentrations of risperidone, 9-hydroxyrisperidone, the total-active-moiety, and the metabolic ratio.

### DISCUSSION

In this study, the associations of DMET genetic markers with steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone among Thai ASD risperidone-treated patients using Affymetrix DMET Plus microarray platform were evaluated. The major findings from this exploratory pharmacogenomic investigation were the abilities of the genetic markers involved in drug metabolism and transport to predict inter-individual variability in steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone. It showed that six polymorphisms (4 *ABCB11* variants and 2 *ADH7* variants) were strongly associated with plasma concentrations of risperidone; six *SLC*
polymorphisms (3 SLCO1B3 variants, 2 SLCO1B1 variants, and 1 SLC7A5 variant) were strongly associated with plasma concentrations of 9-hydroxyrisperidone and the total active-moiety; and four polymorphisms (3 CYP2D6 variants and 1 UGT2B4 variant) were strongly associated with metabolic ratio.

With the increased recognition of the role of transporters in drug disposition with pharmacologically important allelic variability, both ABC and SLC transporters have been the scope of analysis in the present study. These results showed that rs497692, rs496550, rs495714, and rs473351 in ABCB11 were associated with plasma concentrations of risperidone. ABCB11 is a member of the ABC transporter group, subfamily B, member 11, and is also known as sPgp (sister of P-glycoprotein)\(^1\). Although ABCB11 has been studied extensively in other conditions, the report herein found new SNPs of ABCB11

\(^1\)http://www.ncbi.nlm.nih.gov/gene/8647

FIGURE 1 | Manhattan plots of associations of plasma concentrations of risperidone, 9-hydroxyrisperidone, total active-moiety, and metabolic ratio with 483 drug metabolizing enzyme and transporter (DMET) single nucleotide polymorphisms (SNPs). The horizontal x-axis represents the chromosomal positions; the vertical y-axis represents –log\(_{10}\)P-values from the linear regression. The red horizontal line represents the significance level of \(P = 2.5 \times 10^{-5}\) after Bonferroni correction. The horizontal blue line represents the \(P\)-value of 0.01. (A) Manhattan plot showing the significance of DMET SNPs with plasma concentrations of risperidone. (B) Manhattan plot showing the significance of DMET SNPs with plasma concentrations of 9-hydroxyrisperidone. (C) Manhattan plot showing the significance of DMET SNPs with plasma concentrations of total-active moiety. (D) Manhattan plot showing the significance of DMET SNPs with metabolic ratio.
that are associated with plasma concentrations of risperidone. In the study, genes and SNPs that do not have direct interactions with risperidone and its metabolite have been discovered and showed associations with plasma concentrations of risperidone and its metabolite. SNPs related to ADH7 (rs971074 and rs1442477) showed an association with plasma concentrations of risperidone. ADH7 is a class IV alcohol dehydrogenase which metabolizes ethanol to acetaldehyde (Jairam and Edenberg, 2014). The mechanistic functional effects of previously discovered SNPs among the main metabolic polymorphic enzyme CYP2D6 and the major transporter protein ABCB1 did not correlate with the plasma concentrations of risperidone or 9-hydroxyrisperidone as has been reported in earlier studies among the schizophrenic patients (Roh et al., 2001; Jovanovic et al., 2010). This finding implicates the limited importance of CYP2D6 and ABCB1 polymorphisms for the plasma concentrations of risperidone and 9-hydroxyrisperidone. ABCB1 3435C > T polymorphisms, however, were significantly associated with pharmacokinetic parameters (C\textsubscript{max}, AUC, and MR) of risperidone among individuals who were carriers of CYP2D6*10/*10 (Yoo et al., 2011). The reduced function variant CYP2D6*10 which is highly prevalent among Asian populations and associated with plasma concentrations of risperidone (Roh et al., 2001; Vanwong et al., 2016a) failed to pass the QC in the microarray assay. To make these results more conclusive, CYP2D6 variants (rs3892097, rs1065852, and rs28371725) that showed significant influence in pharmacokinetics of risperidone in previous studies were genotyped using the TaqMan assay. The assay found the involvement of CYP2D6 variant alleles in the metabolism of risperidone. The presence of a strong relationship between CYP2D6 variants and metabolism of risperidone in both microarray and TaqMan assays suggests the important role of CYP2D6 genotyping during risperidone treatment.

A cautious approach for the implementation of the information from this study is recommended as many SNPs did not pass the QC step and these SNPs could not be analyzed for associations with plasma concentrations of risperidone and 9-hydroxyrisperidone. A majority of the SNPs were discarded due to the QC filtering criteria of MAF < 0.05. It is likely that rare variants affecting the plasma concentration of risperidone and 9-hydroxyrisperidone might have been missed. Due to the lack of sample size, only the SNPs with a MAF > 0.05 were included and the possibility of false-positive findings was avoided.

The median risperidone dose was relatively lower (0.5 mg/day) along with plasma levels of the total active-moiety (8.48 ng/ml) which are lower than the values reported earlier causing extrapyramidal side effects (EPS; Spina et al., 2001). Linear regression analysis showed a significant influence of the risperidone dose in the plasma concentration of risperidone, 9-hydroxyrisperidone, and the total active-moiety but no effect on the metabolic ratio. The duration of risperidone therapy did not affect the plasma levels of risperidone, 9-hydroxyrisperidone, active-moiety, and metabolic ratio. Age affected the plasma level of 9-hydroxyrisperidone, the total active-moiety, and metabolic ratio. These findings suggest the possible variables responsible for interindividual variations in plasma concentrations of risperidone and its metabolite. Similar findings were reported in an earlier study with a similar effect of age on the plasma concentrations of the total active-moiety (Aichhorn et al., 2005).

**TABLE 6 | Relationship between CYP2D6 variant alleles and the plasma concentrations of risperidone, 9-hydroxyrisperidone, total active-moiety, and metabolic ratio (Sample size = 102).**

| CYP2D6 marker | Risperidone (ng/ml) | 9-hydroxyrisperidone (ng/ml) | Total active-moiety (8.48 ng/ml) | Risperidone/9-hydroxyrisperidone (P-value) |
|---------------|---------------------|-----------------------------|---------------------------------|------------------------------------------|
| c.1846G > A, rs9892067 | 0.39 | 0.9 | 0.22 | 0.37 |
| c.100C > T, rs1065852 | 0.12 | 0.14 | 0.25 | 0.004* |
| c.2989G > A, rs28371725 | 0.009* | 0.9 | 0.74 | 0.26 |

*P-value was considered significant.

In the study, genes and SNPs that do not have direct interactions with risperidone and its metabolite have been discovered and showed associations with plasma concentrations of risperidone and its metabolite. SNPs related to ADH7 (rs971074 and rs1442477) showed an association with plasma concentrations of risperidone. ADH7 is a class IV alcohol dehydrogenase which metabolizes ethanol to acetaldehyde (Jairam and Edenberg, 2014). The mechanistic functional effects of previously discovered SNPs among the main metabolic polymorphic enzyme CYP2D6 and the major transporter protein ABCB1 did not correlate with the plasma concentrations of risperidone or 9-hydroxyrisperidone as has been reported in earlier studies among the schizophrenic patients (Roh et al., 2001; Jovanovic et al., 2010). This finding implicates the limited importance of CYP2D6 and ABCB1 polymorphisms for the plasma concentrations of risperidone and 9-hydroxyrisperidone. ABCB1 3435C > T polymorphisms, however, were significantly associated with pharmacokinetic parameters (C\textsubscript{max}, AUC, and MR) of risperidone among individuals who were carriers of CYP2D6*10/*10 (Yoo et al., 2011). The reduced function variant CYP2D6*10 which is highly prevalent among Asian populations and associated with plasma concentrations of risperidone (Roh et al., 2001; Vanwong et al., 2016a) failed to pass the QC in the microarray assay. To make these results more conclusive, CYP2D6 variants (rs3892097, rs1065852, and rs28371725) that showed significant influence in pharmacokinetics of risperidone in previous studies were genotyped using the TaqMan assay. The assay found the involvement of CYP2D6 variant alleles in the metabolism of risperidone. The presence of a strong relationship between CYP2D6 variants and metabolism of risperidone in both microarray and TaqMan assays suggests the important role of CYP2D6 genotyping during risperidone treatment.

A cautious approach for the implementation of the information from this study is recommended as many SNPs did not pass the QC step and these SNPs could not be analyzed for associations with plasma concentrations of risperidone and 9-hydroxyrisperidone. A majority of the SNPs were discarded due to the QC filtering criteria of MAF < 0.05. It is likely that rare variants affecting the plasma concentration of risperidone and 9-hydroxyrisperidone might have been missed. Due to the lack of sample size, only the SNPs with a MAF > 0.05 were included and the possibility of false-positive findings was avoided.

The median risperidone dose was relatively lower (0.5 mg/day) along with plasma levels of the total active-moiety (8.48 ng/ml) which are lower than the values reported earlier causing extrapyramidal side effects (EPS; Spina et al., 2001). Linear regression analysis showed a significant influence of the risperidone dose in the plasma concentration of risperidone, 9-hydroxyrisperidone, and the total active-moiety but no effect on the metabolic ratio. The duration of risperidone therapy did not affect the plasma levels of risperidone, 9-hydroxyrisperidone, active-moiety, and metabolic ratio. Age affected the plasma level of 9-hydroxyrisperidone, the total active-moiety, and metabolic ratio. These findings suggest the possible variables responsible for interindividual variations in plasma concentrations of risperidone and its metabolite. Similar findings were reported in an earlier study with a similar effect of age on the plasma concentrations of the total active-moiety (Aichhorn et al., 2005).
This study has limitations. The lack of validation of the most significant ($P < 0.01$) DMET variants and association of steady-state plasma concentrations with drug response limits the significance of the study. These results should be verified and clinically interpreted in an independent cohort to avoid the risk of false-positive findings. Also, none of the variants met Bonferroni cutoff value. The exploratory nature of this study, however, suggests the preliminary results to be taken into consideration for further correlation studies. Another limitation is the absence of genomic control which could have false-negative conclusions. The lack of independent validation creates a space for other causative factors, such as age, dosage, and environmental interactions to be implicated for the influence on plasma concentrations of risperidone and its metabolite.

Despite limitations, therapeutic implications from these findings may aid in avoiding toxic plasma levels of risperidone and its metabolite in long term treatment. This pharmacogenomic study provides a mechanistic understanding for individual differences in pharmacokinetics of drugs and may have an outstanding application in the improved personalized treatment of autistic patients in risperidone dosing, efficacy, and side effects. This study opens up the prospect for association of DMET genetic variants with treatment response and adverse effects in future studies. All the patients involved in this study were unrelated which potentially avoided the bias of genotype within families being over-represented.

In summary, this study provides a pharmacogenomic approach to further investigate the DMET genetic variants which influence plasma concentrations of risperidone and its metabolite. The treatment of ASD should be based on genetic factors making the challenge of psychopharmacological treatment more efficacious with fewer adverse events. A caution must be exercised, however, in transferring the pharmacogenomic data into clinical settings unless the genotype-phenotype link is clearly validated.

**AUTHOR CONTRIBUTIONS**

SM, NV, and CS wrote the manuscript; CS, DP, PL, SM, and AP designed the research study; SM, NV, MC, YH, and JP performed
the microarray, genotyping and laboratory part; NN and PL diagnosed and recruited the subjects; SM, CS, and EP analyzed the data.

**FUNDING**

This study was supported by grants from the following organizations: (1) Pharmacogenomics for Autistic Child Project, Khoon Poom Foundation, the Project of Her Royal Highness Princess Ubornratana Rajakanya Siriwatana Bhanawadee; (2) Office of the National Research Council of Thailand; (3) Faculty of Medicine Ramathibodi Hospital; and (4) Mahidol University.

**REFERENCES**

Aichhorn, W., Weiss, U., Marksteiner, J., Kemmler, G., Walch, T., Zernig, G., et al. (2005). Influence of age and gender on risperidone plasma concentrations. *J. Psychopharmacol.* 19, 395–401. doi: 10.1177/026988110503306

Almoguera, B., Rivero-Alvarez, R., Lopez-Castroman, J., Dorado, P., Vaquer-Lorenzo, C., Fernandez-Piquer, J., et al. (2013). Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. *Pharmacogenomics J.* 13, 197–204. doi: 10.1038/tpj.2011.57

Arbitrio, M., Di Martino, M. T., Sciotti, F., Agapito, G., Guzzi, P. H., Cannataro, M., et al. (2016). DMETTM (Drug Metabolism Enzymes and Transporters): a Pharmacogenomic platform for precision medicine. *OncoTarget* doi: 10.18632/oncotarget.9927 [Epub ahead of print]

Aulchenko, Y. S., Ripke, S., Isaacs, A., and van Duijn, C. M. (2007). GenABEL: an R library for genome-wide association analysis. *Bioinformatics* 23, 1294–1296. doi: 10.1093/bioinformatics/btm108

Barrett, J. C., Fry, B., Maller, J., and Daly, M. J. (2005). Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 21, 263–265. doi: 10.1093/bioinformatics/bti021

Bonifaz-Pena, V., Contreras, A. V., Struchiner, C. J., Roela, R. A., Furuya-Mazzotti, T., K., Channaphon, M., et al. (2014). Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations. *PLoS ONE* 9:e112640. doi: 10.1371/journal.pone.0112640

Bowers, K., Lin, P. I., and Erickson, C. (2015). Pharmacogenomic medicine in autism: challenges and opportunities. *Paediatr. Drugs* 17, 115–124. doi: 10.1007/s40272-014-0106-0

Burmester, J. K., Sedova, M., Shapero, M. H., and Mansfeld, E. (2010). DMET microarray technology for pharmacogenomics-based personalized medicine. *Methods Mol. Biol.* 632, 99–124. doi: 10.1007/978-1-60761-663-4_7

Cabaleiro, T., Ochoa, D., Lopez-Rodriguez, R., Roman, M., Novalbos, J., Ayuso, C., et al. (2014). Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. *Hum. Psychopharmacol.* 29, 459–469. doi: 10.1002/hup.2420

Clarke, W. P., Chaveria, T. A., Silva, M., Sullivan, L. C., and Berg, K. A. (2013). Signalling profile differences: paliperidone versus risperidone. *Br. J. Pharmacol.* 170, 532–545. doi: 10.1111/bph.12295

Cohen, D., Raffin, M., Canitano, R., Bodeau, N., Bonnot, O., Perisse, D., et al. (2013). Risperidone or aripiprazole in children and adolescents with autistic spectrum disorder. *Neuropsychiatr. Dis. Treat.* 12, 843–851. doi: 10.2147/NDT.S101580

Nakagami, T., Asai-Furukori, N., Saito, M., Takeishi, T., and Kaneo, S. (2005). Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. *Clin. Pharmacol. Ther.* 78, 43–51. doi: 10.1016/j.clpt.2003.09.009

Nigam, S. K. (2015). What do drug transporters really do? *Nat. Rev. Drug Discov.* 14, 29–44. doi: 10.1038/nrd4461

Riedel, M., Schwarz, M. J., Strassnig, M., Spellmann, I., Muller-Arends, E., Weber, K., et al. (2005). Risperidone plasma levels, clinical response and side-effects. *Eur. Arch. Psychiatry Clin. Neurosci.* 255, 261–268. doi: 10.1007/s00406-004-0556-4

Roh, H. K., Kim, C. E., Chung, W. G., Park, C. S., Svensson, J. O., and Bertilsson, L. (2001). Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. *Eur. J. Clin. Pharmacol.* 57, 671–675. doi: 10.1007/s00228-001-0357

Scordo, M. G., Spina, E., Facciola, G., Avenoso, A., Johanssen, I., and Dahl, M. L. (1999). Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. *Psychopharmacology (Berl)* 147, 300–305. doi: 10.1007/s002130051171

Spina, E., Avenoso, A., Facciola, G., Salemi, M., Scordo, M. G., Ancione, M., et al. (2001). Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. *Psychopharmacology (Berl)* 153, 238–243. doi: 10.1007/s002130005076

Suzuki, T., Fukui, N., Tsuneyama, N., Watanabe, J., Ono, S., Sugai, T., et al. (2012). Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients. *Hum. Psychopharmacol.* 27, 43–46. doi: 10.1002/hup.1260

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fphar.2016.00475/full#supplementary-material

**FIGURE S1 | Multidimensional scaling (MDS) plot of adjacent MDS components.** The plot shows absence of clear population stratification.
Thyssen, A., Vermeulen, A., Fuseau, E., Fabre, M. A., and Mannaert, E. (2010). Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. *Clin. Pharmacokinet.* 49, 465–478. doi: 10.2165/11531730-000000000-00000

Vanwong, N., Ngamsamut, N., Medhasi, S., Puangpetch, A., Chamnanphon, M., Tan-Kam, T., et al. (2016a). Impact of CYP2D6 polymorphism on steady-state plasma levels of risperidone and 9-hydroxyrisperidone in thai children and adolescents with Autism spectrum disorder. *J. Child Adolesc. Psychopharmacol.* doi: 10.1089/cap.2014.0171 [Epub ahead of print].

Vanwong, N., Prommas, S., Puangpetch, A., Hongkaew, Y., Nuntamool, N., Na Nakorn, C., et al. (2016b). Development and validation of Liquid chromatography/tandem mass spectrometry analysis for therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone in pediatric patients with Autism spectrum disorders. *J. Clin. Lab. Anal.* 30, 1236–1246. doi: 10.1002/jcla.22009

Xiang, Q., Zhao, X., Zhou, Y., Duan, J. L., and Cui, Y. M. (2010). Effect of CYP2D6, CYP3A5, and MDRI genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. *J. Clin. Pharmacol.* 50, 659–666. doi: 10.1177/009127009347867

Yasui-Furukori, N., Miura, K., Kondo, T., Kubota, T., Igawa, T., Takarada, Y., et al. (2003). Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. *J. Clin. Pharmacol.* 43, 122–127. doi: 10.1177/00912700239819

Yiannakopoulou, E. (2013). Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications. *Pharmacogenomics J.* 13, 105–109. doi: 10.1038/tpj.2012.42

Yoo, H. D., Lee, S. N., Kang, H. A., Cho, H. Y., Lee, I. K., and Lee, Y. B. (2011). Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10. *Br. J. Pharmacol.* 164, 433–443. doi: 10.1111/j.1476-5381.2011.01385.x

Zhou, S. F., Liu, J. P., and Chowbay, B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. *Drug Metab. Rev.* 41, 89–295. doi: 10.1080/03602530902843483

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Medhasi, Pinthong, Pasomsub, Vanwong, Ngamsamut, Puangpetch, Chamnanphon, Hongkaew, Pratoomwun, Limsila and Sukasem. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.